Compare Adaptive Biotechnologies Corp (ADPT) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Keysight Technologies Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.98 (market cap $3.33B), while Keysight Technologies Inc trades at $311.97 (market cap $52.83B). The key difference: Keysight Technologies Inc is far larger — about 15.9× Adaptive Biotechnologies Corp's market cap. Which is the better fit depends on your goals.
| ADPT | KEYS | |
|---|---|---|
Market Cap | $3.33B | $52.83B |
Sector | Health | Technology |
52-Week High | $22.37 | $373.34 |
52-Week Low | $10.24 | $158.51 |
Enterprise Value | $3.19B | $53.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Keysight Technologies (KEYS) trades at $309.12, down 1.51% today, with a bearish technical signal despite strong earnings beats in recent quarters. The company maintains solid profitability with a 63.67% gross margin and 17.31% net margin, though valuation multiples like a P/E of 51.49 appear elevated. Recent news highlights strategic collaborations in 6G and photonics, positioning KEYS for growth in AI and wireless markets.
The outlook is mixed: analyst consensus is bullish with a $390.30 price target (75% buy ratings), but technical weakness and high valuation pose near-term risks. Upside hinges on execution in high-frequency RF and photonics markets, while downside risks include competitive pressures and integration challenges from acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
